Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
暂无分享,去创建一个
A. Look | T. Hielscher | R. Eferl | U. Jäger | L. Kenner | G. Inghirami | Lawren C. Wu | P. Wolf | O. Merkel | N. Prutsch | P. Staber | R. Moriggl | S. Turner | F. Grebien | Mathias Müller | F. Aberger | B. Strobl | I. Simonitsch-Klupp | T. Sanda | M. Schlederer | C. Kornauth | D. Stoiber | N. Shirsath | Huan-Chang Liang | Elisabeth Gurnhofer | T. Limberger | Tobias Suske | J. Svinka | S. Roos | Dario A Leone | C. Sternberg | J. Schmoellerl | A. Aufinger | A. Álvarez-Hernández | Lawren C. Wu
[1] M. Christie,et al. Loss of NF‐&kgr;B1 Causes Gastric Cancer with Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT‐1‐Dependent Manner , 2018, Immunity.
[2] J. Ahn,et al. Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study , 2018, American journal of hematology.
[3] Ying Zhang,et al. STAT1 in cancer: friend or foe? , 2017, Discovery medicine.
[4] D. Gutmann,et al. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors , 2017, Cancer.
[5] C. V. D. Schoot,et al. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences , 2017, Leukemia.
[6] A. Look,et al. Anti‐leukaemic activity of the TYK2 selective inhibitor NDI‐031301 in T‐cell acute lymphoblastic leukaemia , 2017, British journal of haematology.
[7] T. Waldmann,et al. Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations , 2017, Proceedings of the National Academy of Sciences.
[8] Daniel J. Weisenberger,et al. Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling , 2016, Cell reports.
[9] A. Khwaja,et al. Next-generation sequencing identifies a novel ELAVL1–TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208 , 2016, Leukemia & lymphoma.
[10] S. Verstovsek,et al. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib , 2016, Cancer Chemotherapy and Pharmacology.
[11] S. Mian,et al. Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress , 2016, Nature Communications.
[12] J. French,et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials , 2015, Arthritis Research & Therapy.
[13] A. Look,et al. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia , 2015, Leukemia.
[14] Haifeng Zhang,et al. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. , 2015, Blood.
[15] Suzanne D Turner,et al. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation , 2015, The Journal of pathology.
[16] A. Rosenwald,et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. , 2015, Cancer cell.
[17] K. Elenitoba-Johnson,et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. , 2014, Blood.
[18] Heather L. Mulder,et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.
[19] T. Rülicke,et al. Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance , 2014, Transgenic Research.
[20] Adam R. Johnson,et al. A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors , 2013, The Journal of Immunology.
[21] Angela G. Fleischman,et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. , 2013, Cancer discovery.
[22] K. Khazaie,et al. Tumor STAT1 Transcription Factor Activity Enhances Breast Tumor Growth and Immune Suppression Mediated by Myeloid-derived Suppressor Cells* , 2013, The Journal of Biological Chemistry.
[23] T. Rülicke,et al. TYK2 Kinase Activity Is Required for Functional Type I Interferon Responses In Vivo , 2012, PloS one.
[24] V. Poli,et al. STAT1 and STAT3 in tumorigenesis , 2012, JAK-STAT.
[25] R. Advani,et al. A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies , 2011, Clinical Cancer Research.
[26] V. Sexl,et al. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. , 2011, Frontiers in bioscience.
[27] W. Wilson,et al. A novel role for IL-22R1 as a driver of inflammation. , 2011, Blood.
[28] A. Rosenwald,et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2010, Blood.
[29] R. Weichselbaum,et al. COOPERATIVITY OF THE MUC1 ONCOPROTEIN AND STAT1 PATHWAY IN POOR PROGNOSIS HUMAN BREAST CANCER , 2009, Oncogene.
[30] D. Weisenburger,et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Bernard Roizman,et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. , 2007, Cancer research.
[32] James B. Mitchell,et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. , 2007, Cancer research.
[33] R. Lai,et al. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. , 2006, Blood.
[34] D. Alexander,et al. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. , 2006, Anticancer research.
[35] G. Freeman,et al. Tyk2 Negatively Regulates Adaptive Th1 Immunity by Mediating IL-10 Signaling and Promoting IFN-γ-Dependent IL-10 Reactivation1 , 2006, The Journal of Immunology.
[36] D. Levy,et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.
[37] K. Maclennan,et al. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase , 2003, Oncogene.
[38] T. McDonnell,et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma , 2003, Oncogene.
[39] C. Gambacorti-Passerini,et al. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. , 2003, Experimental hematology.
[40] G. Inghirami,et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. , 2003, Blood.
[41] Diane Lejeune,et al. Interleukin-22 (IL-22) Activates the JAK/STAT, ERK, JNK, and p38 MAP Kinase Pathways in a Rat Hepatoma Cell Line , 2002, The Journal of Biological Chemistry.
[42] J. Darnell,et al. Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.
[43] T. McDonnell,et al. Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. , 2002, The American journal of pathology.
[44] T. McDonnell,et al. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. , 2001, The American journal of pathology.
[45] H. Pircher,et al. Partial impairment of cytokine responses in Tyk2-deficient mice. , 2000, Immunity.
[46] C. Copie-Bergman,et al. Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. , 1998, The American journal of pathology.
[47] P. Nowell,et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[48] J. Darnell,et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.
[49] M. Fellous,et al. A protein tyrosine kinase in the interferon α β signaling pathway , 1992, Cell.
[50] E. Boel,et al. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides , 1992, In Vitro Cellular & Developmental Biology - Animal.
[51] T. Shows,et al. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. , 1990, Oncogene.
[52] Mathias Müller,et al. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene. , 2017, Cytokine.
[53] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[54] Roberto Piva,et al. The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.
[55] P. Gélébart,et al. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma , 2008, Leukemia.